about
A Possible Role for Metallic Ions in the Carbohydrate Cluster Recognition Displayed by a Lewis Y Specific AntibodyA profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization.The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies.Prognostic significance of micrometastatic bone marrow involvement.Detection and clinical importance of micrometastatic disease.Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.Characterization of Two Novel mAbs Recognizing Different Epitopes on CD43.An overview of cancer immunotherapy.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer.Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in miceModulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells.Three-dimensional structures of carbohydrate determinants of Lewis system antigens: implications for effective antibody targeting of cancer.Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.Blood brothers: carbohydrates in xenotransplantation and cancer immunotherapy.Synthesis of chlorin e6-transferrin and demonstration of its light-dependent in vitro breast cancer cell killing ability.
P2860
Q27658123-7004F3AE-514A-4B0A-99B1-C088DC82F675Q30827759-3C5CE9A2-B6ED-4C06-9B89-3C6092F44796Q30864701-8567723B-AA36-4904-BC75-9326E8534CDFQ33538449-9AC4BDA9-B06C-4C96-96E1-224CD661377CQ33678970-C5678E97-9A83-49AB-A6E3-8B698C5697A2Q33803210-73258C86-08B3-43E8-B970-1C2A40BFD06BQ33838833-D49E1B2F-CD93-434F-97BB-CA7D2CF01E7AQ33940388-FE5E8F50-6775-4964-B6C1-86C154FC9D4AQ34451956-DBAA808B-6D62-400D-868E-D75B9731D3EBQ34465224-0223EF10-DB0E-4E02-A708-B4CBDB7D6571Q34719681-288952A6-080B-4B79-99B1-80B1BC156466Q34825919-5D65B4C7-3BC0-46C3-8395-6C88CEEAD384Q36304930-6EC9231F-1C2D-489A-B7F1-F0F2B981F366Q37002044-E228F6C7-25AD-40CB-BB96-734273F0F3B5Q40287396-24EC56B2-CADF-4301-B5FC-E237B9354CBFQ40403692-302505A4-FD91-45E8-A8EB-242A3C494B9FQ44011318-A3FBD3DC-35EA-430A-A1B7-CBCB4C6BABE6
P2860
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Antibody-based immunological therapies.
@en
type
label
Antibody-based immunological therapies.
@en
prefLabel
Antibody-based immunological therapies.
@en
P1476
Antibody-based immunological therapies.
@en
P304
P356
10.1016/S0952-7915(97)80054-4
P577
1997-10-01T00:00:00Z